Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-2-23
pubmed:abstractText
Several attempts have been undertaken to reduce the severity of ischemic myocardial injury by exogenous administration of eicosanoids and by modification of endogenous eicosanoid production. The present study investigates whether defibrotide, a compound that stimulates endogenous prostacyclin (PGI2), has a beneficial effect in experimental ischemic myocardial injury. Anesthetized, open-chest minipigs were subjected to 1 h of coronary artery occlusion, followed by 3 h of reperfusion. Defibrotide (32 mg/kg x h) or its vehicle were infused i.v. throughout the experiment. Defibrotide increased cardiac PGI2 formation 3- to 4-fold greater than control (P < .05). Thromboxane levels remained unchanged. Irreversible ischemic injury, as identified by negative tetrazolium staining, amounted to 44 +/- 6% of the area at risk in pigs receiving vehicle but was reduced to 23 +/- 4% by defibrotide (P < .05). This reduced tissue injury in defibrotide-treated pigs was associated with improved functional recovery (left ventricular pressure, + dP/dtmax), during early reperfusion. Recovery did not occur in vehicle-treated pigs. Collagen (2 micrograms/ml)-induced platelet aggregation ex vivo was increased in vehicle-treated pigs during ischemia and reperfusion, but not in animals treated with defibrotide. Polymorphonuclear neutrophil leukocyte accumulation in the ischemic border zone was reduced from 59 +/- 17 cells/mm2 in vehicle-treated pigs to 17 +/- 9 cells/mm2 by defibrotide (P < .05). Pretreatment of the animals with indomethacin (3 mg/kg) prevented the reduction of infarct size and polymorphonuclear neutrophil leukocyte infiltration by defibrotide. Indomethacin increased infarct size in vehicle- and defibrotide-treated pigs by 71 and 59%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0022-3565
pubmed:author
pubmed:issnType
Print
pubmed:volume
264
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
397-405
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:8423539-6-Ketoprostaglandin F1 alpha, pubmed-meshheading:8423539-Animals, pubmed-meshheading:8423539-Blood Platelets, pubmed-meshheading:8423539-Cyclooxygenase Inhibitors, pubmed-meshheading:8423539-Disease Models, Animal, pubmed-meshheading:8423539-Epoprostenol, pubmed-meshheading:8423539-Female, pubmed-meshheading:8423539-Granulocytes, pubmed-meshheading:8423539-Indomethacin, pubmed-meshheading:8423539-Leukocyte Count, pubmed-meshheading:8423539-Male, pubmed-meshheading:8423539-Myocardial Infarction, pubmed-meshheading:8423539-Myocardial Ischemia, pubmed-meshheading:8423539-Myocardial Reperfusion Injury, pubmed-meshheading:8423539-Myocardium, pubmed-meshheading:8423539-Neutrophils, pubmed-meshheading:8423539-Platelet Count, pubmed-meshheading:8423539-Polydeoxyribonucleotides, pubmed-meshheading:8423539-Prostaglandins, pubmed-meshheading:8423539-Stimulation, Chemical, pubmed-meshheading:8423539-Swine, pubmed-meshheading:8423539-Swine, Miniature, pubmed-meshheading:8423539-Thromboxane A2, pubmed-meshheading:8423539-Ventricular Function, Left
pubmed:year
1993
pubmed:articleTitle
Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury.
pubmed:affiliation
Institut für Pharmakologie, Heinrich-Heine Universität Düsseldorf, FRG.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't